These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

416 related articles for article (PubMed ID: 30185157)

  • 1. Correlation between family physician's direct advice and pneumococcal vaccination intention and behavior among the elderly in Japan: a cross-sectional study.
    Higuchi M; Narumoto K; Goto T; Inoue M
    BMC Fam Pract; 2018 Sep; 19(1):153. PubMed ID: 30185157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) revaccination coverage rate among elderly adults aged 65 and older and physician's attitude.
    Nakamura A; Kawakami K; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Sep; 16(9):2292-2299. PubMed ID: 32045317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
    Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
    Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Japanese nationwide survey of 23-valent pneumococcal capsular polysaccharide vaccine (PPSV23) coverage among patients with chronic medical condition aged 50 and older.
    Kawakami K; Nakamura A; Wakana A; Folaranmi TA; Iino T
    Hum Vaccin Immunother; 2020 Jul; 16(7):1521-1528. PubMed ID: 31799889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uptake of pneumococcal polysaccharide vaccination among working-age adults with underlying medical conditions, United States, 2009.
    Lu PJ; Nuorti JP
    Am J Epidemiol; 2012 Apr; 175(8):827-37. PubMed ID: 22403807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pneumococcal vaccination strategies for the elderly in Korea.
    Heo JY; Seo YB; Choi WS; Lee J; Noh JY; Jeong HW; Kim WJ; Kim MJ; Lee HY; Song JY
    PLoS One; 2017; 12(5):e0177342. PubMed ID: 28498857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey.
    Murakami Y; Kanazu S; Petigara T; Oba MS; Nishiwaki Y; Watanabe A
    BMJ Open; 2019 Jul; 9(7):e030197. PubMed ID: 31315877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on elderly long-term cancer survivors: a population-based propensity score matched cohort study.
    Chiou WY; Lee MS; Hung SK; Lin HY; Lo YC; Hsu FC; Tsai SJ; Li CY
    BMJ Open; 2018 May; 8(5):e019364. PubMed ID: 29769253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study.
    Suzuki K; Kondo K; Washio M; Nakashima K; Kan S; Imai S; Yoshimura K; Ota C; Ohfuji S; Fukushima W; Hirota Y
    Hum Vaccin Immunother; 2019; 15(9):2171-2177. PubMed ID: 30785356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal vaccination, but not influenza vaccination, is negatively associated with incident dementia among Japanese older adults: The JAGES 2013-2022 prospective cohort study.
    Iwai-Saito K; Sato K; Fujii M; Kondo K
    Brain Behav Immun; 2024 Aug; 120():452-463. PubMed ID: 38925416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addressing Pneumococcal Vaccine Uptake Disparities among African-American Adults in the United States.
    Fry CA; Silverman EP; Miller S
    Public Health Nurs; 2016 Jul; 33(4):277-82. PubMed ID: 27103181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of pneumococcal vaccination with cardiovascular diseases in older adults: The vaccine effectiveness, networking, and universal safety (VENUS) study.
    Narii N; Kitamura T; Komukai S; Zha L; Komatsu M; Murata F; Maeda M; Kiyohara K; Sobue T; Fukuda H
    Vaccine; 2023 Mar; 41(13):2307-2313. PubMed ID: 36870877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with pneumococcal vaccination among an urban elderly population in China.
    Liu S; Xu E; Liu Y; Xu Y; Wang J; Du J; Zhang X; Che X; Gu W
    Hum Vaccin Immunother; 2014; 10(10):2994-9. PubMed ID: 25483646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of pneumococcal and influenza vaccination coverage in rheumatology patients receiving biological therapy in a regional referral hospital.
    Fernández-Prada M; Brandy-García AM; Rodríguez-Fonseca OD; Huerta-González I; Fernández-Noval F; Martínez-Ortega C
    Reumatol Clin (Engl Ed); 2020; 16(2 Pt 1):97-102. PubMed ID: 29752214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with pneumococcal vaccine uptake in elderly subjects referred to the respiratory department.
    Watanabe K; Asai Y; Tsurikisawa N; Oshikata C; Kaneko T
    Nagoya J Med Sci; 2020 Aug; 82(3):469-476. PubMed ID: 33132431
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China.
    Zhao D; Gai Tobe R; Cui M; He J; Wu B
    Vaccine; 2016 Dec; 34(50):6158-6165. PubMed ID: 27838068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study.
    De Montalembert M; Abboud MR; Fiquet A; Inati A; Lebensburger JD; Kaddah N; Mokhtar G; Piga A; Halasa N; Inusa B; Rees DC; Heath PT; Telfer P; Driscoll C; Al Hajjar S; Tozzi A; Jiang Q; Emini EA; Gruber WC; Gurtman A; Scott DA
    Pediatr Blood Cancer; 2015 Aug; 62(8):1427-36. PubMed ID: 25810327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions.
    Cho BH; Stoecker C; Link-Gelles R; Moore MR
    Vaccine; 2013 Dec; 31(50):6011-21. PubMed ID: 24148572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group.
    Svensson T; Kättström M; Hammarlund Y; Roth D; Andersson PO; Svensson M; Nilsson I; Rombo L; Cherif H; Kimby E
    Vaccine; 2018 Jun; 36(25):3701-3707. PubMed ID: 29748028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.